# Recursion Pharmaceuticals, Inc. (RXRX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.40B  
**Price:** $3.14 (+3.29%)

> Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on using automation, artificial intelligence, machine learning, and data science to discover novel medicines. Recursion Pharmaceuticals develops a technology-driven drug discovery platform that combines biology, chemistry, engineering, and computational tools to identify potential drug candidates, study mechanisms of action, and evaluate safety signals. Its work centers on industrializing the process of discovering therapeutics for serious diseases, with programs that span multiple research areas within the life sciences. The company operates as a biotechnology platform business, supporting both internal drug development and broader scientific applications through its integrated Recursion operating system. Headquartered in Salt Lake City, Utah, and founded in 2013, Recursion Pharmaceuticals plays a distinctive role in the market by merging advanced computing with experimental biology to accelerate modern drug discovery.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $75M | $4M | -$648M | -$645M | — |
| 2024 | $59M | $14M | -$479M | -$464M | — |
| 2023 | $45M | $2M | -$350M | -$328M | — |
| 2022 | $40M | -$8M | -$246M | -$239M | — |
| 2021 | $10M | $10M | -$183M | -$186M | — |
| 2020 | $4M | $4M | -$85M | -$87M | — |
| 2019 | $2M | — | -$62M | -$62M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.47B | $343M | $1.13B | $743M | — |
| 2024 | $1.45B | $414M | $1.03B | $594M | — |
| 2023 | $654M | $190M | $463M | $392M | — |
| 2022 | $701M | $215M | $486M | $550M | — |
| 2021 | $610M | $67M | $543M | $285M | $723,000 |
| 2020 | $299M | $57M | -$206M | $262M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$372M | $6M | -$378M |
| 2024 | -$359M | $14M | -$373M |
| 2023 | -$288M | $12M | -$300M |
| 2022 | -$84M | $37M | -$121M |
| 2021 | -$159M | $40M | -$198M |
| 2020 | -$45M | $6M | -$51M |
| 2019 | -$57M | $4M | -$61M |

Source: [CompaniesByCap](https://companiesbycap.com/company/RXRX)